<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02261077</url>
  </required_header>
  <id_info>
    <org_study_id>202.833</org_study_id>
    <nct_id>NCT02261077</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Safety and Tolerability of Rising Doses of Buscopan® in Healthy Male Volunteers</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled Study to Assess Pharmacokinetics, Safety and Tolerability of Single Rising Oral Doses (20 mg, 60 mg, 100 mg, 200 mg and 400 mg) and Multiple Rising Oral Doses (3 x 20 mg, 3 x 60 mg and 3 x 100 mg Per Day) of Buscopan® in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to investigate pharmacokinetics, safety and tolerability of Buscopan® after single
      rising dose and after multiple rising doses
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum measured concentration of analyte in plasma (Cmax)</measure>
    <time_frame>up to 104 hours after last drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)</measure>
    <time_frame>up to 104 hours after last drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of analyte eliminated in urine from the time point t1 to time point t2 (Aet1-t2)</measure>
    <time_frame>up to 80 hours after last drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time from dosing to maximum measured concentration (tmax)</measure>
    <time_frame>up to 104 hours after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of the analyte in plasma over a uniform dosing interval τ after administration of the first dose (AUCτ,1)</measure>
    <time_frame>up to 32 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal rate constant in plasma (λz)</measure>
    <time_frame>up to 104 hours after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life of the analyte in plasma (t1/2)</measure>
    <time_frame>up to 104 hours after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time of the analyte in the body (MRTpo)</measure>
    <time_frame>up to 104 hours after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total/apparent clearance in plasma after extravascular administration (CL/F)</measure>
    <time_frame>up to 104 hours after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution during the terminal phase λz following an extravascular dose (Vz/F)</measure>
    <time_frame>up to 104 hours after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of analyte eliminated in urine from the time point t1 to time point t2 (Aet1-t2)</measure>
    <time_frame>up to 80 hours after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of analyte eliminated in urine from time point t1 to time point t2 (fet1-t2)</measure>
    <time_frame>up to 80 hours after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal clearance of the analyte from the time point t1 until the time point t2 (CLR,t1-t2)</measure>
    <time_frame>up to 80 hours after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average concentration of the analyte in plasma at steady-state (Cavg)</measure>
    <time_frame>up to 104 hours after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmin,ss)</measure>
    <time_frame>up to 104 hours after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predose concentration of the analyte in plasma at steady state immediately before administration of the next dose (Cpre,ss)</measure>
    <time_frame>predose on days 1-4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linearity index (LI)</measure>
    <time_frame>up to 104 hours after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio (RA) based on Cmax (RA,Cmax,N)</measure>
    <time_frame>up to 104 hours after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RA,AUC,N based on AUC0-τ</measure>
    <time_frame>up to 104 hours after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with clinically relevant findings in vital sign parameters (blood pressure (BP), pulse rate (PR))</measure>
    <time_frame>up to 14 days after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with clinically relevant findings in 12-lead electrocardiogram</measure>
    <time_frame>up to 14 days after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with abnormal changes in laboratory parameters</measure>
    <time_frame>up to 14 days after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with abnormal findings in physical examination</measure>
    <time_frame>up to 14 days after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events</measure>
    <time_frame>up to 47 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability assessed by investigator on a 4-point scale</measure>
    <time_frame>within 14 days after last drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Buscopan, single rising doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Buscopan, multiple rising doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyoscine butylbromide</intervention_name>
    <arm_group_label>Buscopan, single rising doses</arm_group_label>
    <arm_group_label>Buscopan, multiple rising doses</arm_group_label>
    <other_name>Buscopan®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy males based upon a complete medical history, including the physical
             examination, vital signs (BP, PR), 12-lead ECG, clinical laboratory tests. There is no
             finding deviating from normal and of clinical relevance. There is no evidence of a
             clinically relevant concomitant disease.

          2. Age ≥21 and age ≤50 years

          3. BMI ≥18.5 and BMI &lt;30 kg/m2 (Body Mass Index)

          4. Signed and dated written informed consent prior to admission to the study in
             accordance with Good Clinical Practice and the local legislation

        Exclusion Criteria:

          1. Any finding of the medical examination (including BP, PR and ECG) deviating from
             normal and of clinical relevance

          2. Evidence of a clinically relevant concomitant disease

          3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          4. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          5. History of relevant orthostatic hypotension, fainting spells or blackouts

          6. Chronic or relevant acute infections

          7. History of relevant allergy/hypersensitivity (including allergy to drug or its
             excipients) as judged clinically relevant by the investigator

          8. Intake of drugs with a long half-life (&gt; 24 hours) within at least one month or less
             than 10 half-lives of the respective drug prior to randomization

          9. Use of drugs which might reasonably influence the results of the trial based on the
             knowledge at the time of protocol preparation within 10 days prior to enrolment in the
             study or during the study

         10. Participation in another trial with an investigational drug within two months prior to
             randomization

         11. Smoker (&gt; 10 cigarettes or &gt; 3 cigars or &gt; 3 pipes/day)

         12. Inability to refrain from smoking on trial days as judged by the investigator

         13. Alcohol abuse (more than 40 g/day for males)

         14. Drug abuse

         15. Blood donation (more than 100 mL within four weeks prior to administration or during
             the trial)

         16. Excessive physical activities within one week prior to administration or during the
             trial

         17. Any laboratory value outside the reference range that is of clinical relevance

         18. Inability to comply with dietary regimen of trial site

         19. Hypersensitivity to hyoscine butylbromide and/or related drugs of these classes

         20. History of megacolon

         21. History of prostatic hyperplasia

         22. History of mechanical stenosis of the gastrointestinal (e.g. after surgery of the
             gastrointestinal tract)

         23. History of narrow-angle glaucoma

         24. History of tachycardic arrhythmias

         25. History of myasthenia gravis

         26. Bladder-neck obstruction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2014</study_first_submitted>
  <study_first_submitted_qc>October 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2014</study_first_posted>
  <last_update_submitted>October 9, 2014</last_update_submitted>
  <last_update_submitted_qc>October 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Butylscopolammonium Bromide</mesh_term>
    <mesh_term>Scopolamine Hydrobromide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

